Mutation Frequencies of the Cytochrome CYP2D6 Gene in Parkinson Disease Patients and in Families

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 67, Issue 4, 1996, Pages 361-365

  Lucotte, G ^a,b,d   Turpin, J C ^a,b   Gerard N ^c   Panserat, S ^c   Krishnamoorthy, R ^c  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d HÔPITAL MAISON BLANCHE   (France)

Author keywords

Cytochrome P450 CYP2D6 gene; Mutations D6 A, B, C, D, and T; Parkinson disease; Poor metabolizer alleles; Studies in families

Indexed keywords

CYTOCHROME;

ALLELE; ARTICLE; FAMILIAL DISEASE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; CONFIDENCE INTERVALS; CYTOCHROME P-450 CYP2D6; FAMILY; FEMALE; GENOTYPE; HUMANS; MALE; MUTATION; PARKINSON DISEASE; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REFERENCE VALUES; RISK FACTORS;

EID: 0029846366     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19960726)67:4<361::AID-AJMG8>3.0.CO;2-P     Document Type: Article

References (25)

1. Agúndez JAG, Jiménez FJ, Luengo A (1995): Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 57:291-298.
2. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR (1992): Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339:1017-1018.
3. Barbeau A, Cloutier T, Roy M (1985): Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 8466:1213-1216.
4. Benitez J, Ladero JM, Jiménez FJ (1990): Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 53:289-292.
5. Broly F, Gaedigk A, Heim M (1991): Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558.
6. Eichelbaum M, Gross AS (1990): The genetic polymorphism of debrisoquine-sparteine metabolism: Clinical aspects. Pharmacol Ther 46: 377-394.
7. Fonne-Pfister R, Bargetzi MJA, Meyer UA (1987): MPTP, the neurotoxin inducing Parkinson's disease, is a potent inhibitor of human and rat P450 enzymes catalysing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148:1144-1150.
8. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991): Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine-sparteine polymorphism. Am J Hum Genet 48:943-950.
9. Gasser T, Wszolek ZK, Trofatter J, Ozllius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO (1994): Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes. Ann Neurol 36:387-396.
10. Heim M, Meyer UA (1990): Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532.
11. Hughes AJ, Ben Shlomo Y, Daniel SE, Less AJ (1992): What features improve the accuracy of clinical diagnosis in Parkinson's disease? A clinico-pathologic study. Neurology 42:1142-1146.
12. Islam SA, Wolf CR, Lennard MS, Sternberg MJE (1991): A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12:2211-2219.
13. Jenner P, Schapira AHV, Marsden CD (1992): New insights into the cause of Parkinson's disease. Neurology 42:2241-2250.
14. Johnson WG (1991): Genetic susceptibility to Parkinson's disease. Neurology [Suppl] 41:82-87.
15. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990): Multiple mutations of the human cytochrome P450IID6 gene in poor metabolizers of debrisoquine: Study of the functional significance of individual mutations by expression of chimeric genes. J Biochem (Tokyo) 265:17209-17216.
16. Kurth MC, Kurth JH (1993): Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 48: 166-168.
17. 3H]GBR-12935 binding proteins. Arch Biochem Biophys 276:424-432.
18. Planté-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE (1994): Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 57:911-913.
19. Planté-Bordeneuve V, Taussig D, Thomas F, Ziégler M, Saïd G (1995): A clinical and genetic study of familial cases of Parkinson's disease. J Neurol Sci 133:164-172.
20. Poirier J, Roy M, Campanella G (1987): Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs. Lancet 8555:386.
21. Saxena R, Shaw GL, Relling MV (1994): Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:223-226.
22. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988): Two mutant alleles of human cytochrome P450 gene associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-5243.
23. Smith CAD, Gough AC, Leigh PN (1992): Association between the CYP2D6-debrisoquine hydroxylase polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377.
24. Tanner CM (1991): Abnormal liver enzyme-mediated metabolism in Parkinson's disease: A second look. Neurology [Suppl] 41:89-91.
25. Tyndale R, Aoyama T, Broly F (1991): Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26-32.